Slide 1: Oncoinvent
Oncoinvent Pioneering targeted alpha therapies to prevent cancer recurrence after surgery Second Half 2025 update February 26, 2026
Slide 2: Disclaimer and important information
Disclaimer and important information This presentation (the “Presentation”) has been prepared by Oncoinvent ASA (the “Company”) for information purposes only and does not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities of the Company
Slide 3: Introduction
Introduction Highlights Clinical Update Financials Q&A
Slide 4: Unmet medical need
Unmet medical need Peritoneal metastases - urgent need for novel treatments o Peritoneal metastases arise from many different primary cancers o The only treatment option with curative intent is surgery, effect of systemic therapy limited o Surgery leaves behind micro-metastases giving rise to new me
Slide 5: Unmet medical need
Unmet medical need The main cause of death in ovarian cancer o Despite a comprehensive treatment approach, the majority of patients experience disease recurrence o Ovarian cancer rarely metastasize hematogenously, recurrences almost exclusively confined to the peritoneum o Need for improved first-li
Slide 6: Treatment concept
Treatment concept Radspherin® - alpha therapy targeted to and retained in the peritoneum Radspherin® o Combining alpha-emitting 224Ra with CaCO3 microparticles o Half-life 3.6 days o Therapy with depot effect - 75% of radiation dose delivered the first week o Shelf life 8 days allowing for centraliz
Slide 7: Treatment concept
Treatment concept Radspherin® - alpha therapy targeted to and retained in the peritoneum Radspherin® How does it work? o Combining alpha-emitting 224Ra with o Delivering a high dose of alpha-radiation CaCO3 microparticles directly to the peritoneum through an in- dwelling catheter o Half-life 3.6 da
Slide 8: Highlights
Introduction Highlights Clinical Update Financials Q&A
Slide 9: Recent Highlights
Recent Highlights o Reported positive final data from Phase 1 trial of Radspherin® to treat ovarian cancer - Published results in Gynecologic Oncology - Presented at ESGO European Gynaecological Oncology Congress 2026 o Recruited and randomized 26 patients (accumulated, ITT) into the ovarian Phase 2
Slide 10: Clinical Update
Introduction Highlights Clinical Update Financials Q&A
Slide 11: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Interim Final Colorectal Final Ph 2 Ovarian ~110 patients Interim Interim Final Completed Upcoming milestones
Slide 12: Ovarian cancer: Preventing disease progression
Ovarian cancer: Preventing disease progression 24 months data from 10 patients receiving 7 MBq dose vs historical recurrence rates Recurrence rate Historical controls “These final results are truly encouraging, suggesting that 10 % 30 % Radspherin® could help delay disease progression and offer pati
Slide 13: Randomized Phase 2 study in first-line treatment of ovarian cancer
Randomized Phase 2 study in first-line treatment of ovarian cancer Patient population o Primary advanced ovarian Randomised SoC+ Radspherin Primary cancer Safety Imaging every 3 cohort endpoint: o Undergoing neoadjuvant run-in 2:1 months up to 24 ~110 ITT progression-free chemotherapy and interval 6
Slide 14: Patient recruitment update end 2025 Ph2 Ovarian study
Patient recruitment update end 2025 Ph2 Ovarian study Progress so far The road ahead o A total of 26 patients (of approx. 110) per intention to treat have been recruited and o One additional hospital will be added randomized end December in 1H 2026 for a total of 11 sites o Ten hospitals are active.
Slide 15: Addition to the management team
Addition to the management team o CFO of the Company since mid-January 2026 o Responsible for finance, business development and strategic planning o Last role: VP, Head of Development Strategy & Execution at Galapagos (Netherlands) o 7 years at McKinsey & Company advising global pharma/biotech, plus
Slide 16: Financials
Introduction Highlights Clinical Update Financials Q&A
Slide 17: Financials
Financials Financial performance AMOUNTS IN 1 000 NOK 2H 2025 2H 2024 FY 2025 FY 2024 o Post-merger cash position just under (rounded to next million) unaudited NOK 180m NOK at year end o Cash runway into 2027; beyond planned Total operating revenue 16 8 28 8 Phase 2 interim analysis o Operating los
Slide 18: Financial Calendar
Financial Calendar 22 April Annual Report 29 April Q1 update and presentation 20 May Annual General Meeting 27 August H1 report and presentation 28 October Q3 update and presentation
Slide 19: Q&A
Introduction Highlights Clinical Update Financials Q&A